Skip to main content

Clinical Trials Using Anti-HER3/Topoisomerase I Inhibitor Antibody-drug Conjugate

Review the clinical trials studying anti-her3/topoisomerase I inhibitor antibody-drug conjugate on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-14 of 14

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Status: Active
Location: 7 locations
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
Status: Active
Location: 8 locations
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Status: Active
Location: 5 locations
U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer
Status: Active
Location: 5 locations
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Status: Active
Location: 3 locations
Patritumab Deruxtecan for the Treatment of Patients with Newly Diagnosed or Recurrent Brain Metastases
Status: Active
Location: Duke University Medical Center, Durham, North Carolina
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
Status: Active
Location: University of Kentucky/Markey Cancer Center, Lexington, Kentucky
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
Status: Active
Location: 2 locations
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ENV-501 in Patients With HER3-Expressing Solid Tumors
Status: Active
Location: UC San Diego Moores Cancer Center, La Jolla, California
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Status: Active
Location: 6 locations
A Study of DM002 in Patients With Advanced Solid Tumors
Status: Active
Location: 2 locations
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Status: Active
Location: See ClinicalTrials.gov
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Status: Active
Location: See ClinicalTrials.gov